Related Experiment Videos

Should albuminuria be a therapeutic target in patients with hypertension and diabetes?

Dick de Zeeuw1

  • 1Department of Clinical Pharmacology, University Medical Center, Groningen, the Netherlands. d.de.zeeuw@med.rug.nl

American Journal of Hypertension
|November 13, 2004
PubMed

Insights

Controlling high blood pressure and reducing albuminuria are key to preventing cardiovascular and kidney disease in type 2 diabetes. Renin-angiotensin-aldosterone system blockers are recommended for optimal patient outcomes.

Area of Science:

  • Nephrology
  • Cardiology
  • Endocrinology

Background:

  • Diabetes complications like cardiovascular and renal disease are linked to hypertension, dyslipidemia, hyperglycemia, and smoking.
  • Albuminuria is an emerging risk factor, independently associated with increased cardiovascular and renal risk.
  • Inhibition of the renin-angiotensin-aldosterone system (RAAS) lowers blood pressure and albuminuria, offering cardiovascular and renal protection independent of blood pressure reduction.

Purpose of the Study:

  • To outline optimal therapeutic strategies for patients at risk for type 2 diabetic nephropathy.
  • To emphasize the importance of blood pressure and albuminuria control in managing diabetic kidney disease.
  • To highlight the role of RAAS inhibition in achieving therapeutic goals.

Main Methods:

  • Review of existing literature on risk factors for diabetic cardiovascular and renal complications.
  • Analysis of the impact of RAAS inhibition on blood pressure and albuminuria.
  • Synthesis of evidence to recommend treatment targets for blood pressure and albuminuria.

Main Results:

  • RAAS inhibition effectively reduces both blood pressure and albuminuria.
  • Cardiovascular and renal protection are associated with albuminuria reduction, independent of blood pressure changes.
  • Optimal therapy requires blood pressure below 130/80 mm Hg and urinary albumin below 500 mg/d.

Conclusions:

  • Optimal management of type 2 diabetic nephropathy necessitates aggressive blood pressure control (<130/80 mm Hg).
  • Inclusion of RAAS blocking agents, such as angiotensin II receptor blockers, is crucial for BP and urinary albumin control.
  • Reducing urinary albumin to <500 mg/d is a key therapeutic target for renal and cardiovascular protection.

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...